Kan Gruplarının SARS-CoV-2 Enfeksiyonu ve Prognozu Üzerine Etkisi

Öz

Amaç: Bu çalışmanın amacı, asıl/kaynak vakalar ve temaslı olan vakalarda kan gruplarının Ciddi Akut Solunum Yolu Sendromu 2 (SARS-CoV-2) riskini ve prognozu nasıl etkilediğini araştırmaktır.
Materyal ve Metot: Çalışmamız tanımlayıcı retrospektif olarak planlanmıştır. SARS-CoV-2 bulunan asıl/kaynak vakalar ile temaslı olup evde takip edilen bireyler dahil edilmiştir. Katılımcıların kan gruplarına göre dağılımları incelenmiştir. Hastalar 1.grup, kaynak/asıl vakalardan, 2.grup ev içi temaslı olup karantina sürecinde SARS-CoV-2 olan hastalar, 3.grup ev içi temaslı olup karantina sürecinde SARS-CoV-2 gelişmeyen bireyler olarak üç gruba ayrıldı.
Bulgular: Çalışmaya 1451 kişi dâhil edilmiştir. Yaş ortancası 41 idi. Gruplar arasında ABO kan grupları açısından fark yoktu ama A kan grubu 1. Grupta (% 45.4) en fazla orandaydı (p:0.61). Non-O kan grubu 2.grupta (%39.4) en fazla iken, O kan grubu da 3.grupta (%42.8) en fazla idi (p: 0.028). Rh pozitif kan grubu 1. grupta fazla idi. Rh negatif kan grubu 3. grupta daha fazla idi (p:0.000). Rh (+) kan grubu (OR:0.464, p: 0.010 ,%95 Cl: 0.306 ~ 0.703) ev içi temaslı olan vakalarda takipte enfeksiyon gelişmesini etkileyen faktörlerdendi.
Sonuç: SARS-CoV-2 ile enfekte olan hastalarda büyük oranda A, Non-O kan grubu ve Rh pozitifliği vardı. Yüksek risk taşıyan ev içi temaslılarda Rh (+) kan grubuna sahip olma enfeksiyon gelişme oranını artırmış olabilir. Bu kan grubundaki hastaların temaslı olduğu tespit edildikten sonra daha yakın takip edilmesi morbiditeyi azaltmak için gerekebilir.

Anahtar Kelimeler

• Kan grubu
• Rh
• SARS-COV2
• ABO
• Clinical outcome

The Effect of Blood Groups on Infection and Prognosis of SARS-CoV-2

Öz

Aim: This study aimed to investigate the effect of blood groups on the risk and prognosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the infected/source cases and contact individuals.
Material and Method: This study was designed as a descriptive and retrospective study. The individuals who were in contact with the SARS-CoV-2main/source cases and followed at home were included in the study.The distribution of the participants according to their blood groups was assessed. Patients were divided into three groups as group 1 including source/main cases, group 2 including SARS-CoV-2contacts who were living in the same house with the source case and followed up, and group 3 including contacts who were followed up in the same house but did not develop SARS-CoV-2 during the follow-up.
Results: While the rate of Non-O blood group was the highest (n=365, 39.4%) in group 2the rate of O blood group was the highest (n=190, 42.8%) in group 3 (p:0.028). While the rate of Rh positive blood group was high in group 1 that of Rh negative blood group was higher in group 3 (p:0.000). For other variables, the presence of a chronic disease was more in group 1 (p:0.000). Rh (+) blood group (OR:0.464, p:0.010, %95 Cl: 0.306 ~ 0.703) was among the factors affecting the development of the infection.
Conclusion: Patients infected with SARS-CoV-2 mostly had A, Non-O blood group and Rh positivity. Having Rh (+) blood group may have increased the rate of infection development in high-risk household contacts. After patients in this blood group were detected as contacts a closer follow-up may be necessary to decrease morbidity.

Anahtar Kelimeler

• Blood group
• Rh
• SARS-COV2
• ABO
• Clinical Outcome

Kaynakça

1. 1. Holmes KV, Lai MMC, et al. Fields Virology. 1996. Coronaviridae; pp. 1075–1093.
2. 2. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953-1966. doi:10.1056/NEJMoa03078.
3. 3. de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013;87(14):7790-7792. doi:10.1128/JVI.01244-13
4. 4. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017
5. 5. Zhao J, Yang Y, Huang H, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility [published online ahead of print, 2020 Aug 4]. Clin Infect Dis. 2020;ciaa1150. doi:10.1093/cid/ciaa1150
6. 6. Avent ND, Reid ME. The Rh blood group system: a review [published correction appears in Blood 2000 Apr 1;95(7):2197]. Blood. 2000;95(2):375-387. 7. Franchini M, Capra F, Targher G, Montagnana M, Lippi G. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J. 2007;5:14. Published 2007 Sep 25. doi:10.1186/1477-9560-5-14
7. 8. Franchini M, Favaloro EJ, Targher G, Lippi G. ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev Clin Lab Sci. 2012;49(4):137-149. doi:10.3109/10408363.2012.708647
8. 9. Harris JB, Khan AI, LaRocque RC, et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun. 2005;73(11):7422-7427. doi:10.1128/IAI.73.11.7422-7427.2005.

9. 10. Göker H, Aladağ Karakulak E, Demiroğlu H, et al. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. Turk J Med Sci. 2020;50(4):679-683. Published 2020 Jun 23. doi:10.3906/sag-2005-395
10. 11. Anstee DJ. The relationship between blood groups and disease. Blood. 2010;115(23):4635-4643.
11. 12. Cheng Y, Cheng G, Chui CH, et al. ABO blood group and susceptibility to severe acute respiratory syndrome [published correction appears in JAMA. 2005 Aug 17;294(7):794. Cheng, Yufeng [corrected to Cheng, Yunfeng]]. JAMA. 2005;293(12):1450-1451. doi:10.1001/jama.293.12.1450-c
12. 13. Cserti CM, Dzik WH. The ABO blood group system and Plasmodium falciparum malaria. Blood. 2007;110(7):2250-2258. doi:10.1182/blood-2007-03-077602
13. 14. Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB. ABO blood group and cancer. Eur J Cancer. 2010;46(18):3345-3350. doi:10.1016/j.ejca.2010.08.009
14. 15. Liu J, Zhang S, Liu M, Wan Q, Shen H, Zhang Y. Distribution of ABO/Rh blood groups and their association with hepatitis B virus infection in 3.8 million Chinese adults: A population-based cross-sectional study. J Viral Hepat. 2018;25(4):401-411. doi:10.1111/jvh.12829
15. 16. Arac E, Solmaz IH, Akkoc H, et al. Association Between the Rh Blood Group and the Covid-19 Susceptibility. Int J Hematol Oncol. 2020;30(2):81–6. doi: 10.4999/uhod.204247.
16. 17. Golinelli D, Boetto E, Maietti E, Fantini MP. The association between ABO blood group and SARS-CoV-2 infection: A meta-analysis. PLoS One. 2020;15(9):e0239508. Published 2020 Sep 18. doi:10.1371/journal.pone.0239508
17. 18. Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun. 2020;11(1):5761. Published 2020 Nov 13. doi:10.1038/s41467-020-19623-x
18. 19. Torun YA, Kaynar LG, Karakükcü C, et al. ABO and Rh Blood Group Distribution in Kayseri Province, Turkey. Turk J Haematol. 2012;29(1):97-98. doi:10.5505/tjh.2012.26918
19. 20. Wu Y, Feng Z, Li P, Yu Q. Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19. Clin Chim Acta. 2020;509:220-223. doi:10.1016/j.cca.2020.06.026
20. 21. Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Br J Haematol. 2020;190(1):24-27. doi:10.1111/bjh.16797
21. 22. Yaylacı S, Dheir H, İşsever K, et al. The effect of abo and rh blood group antigens on admission to intensive care unit and mortality in patients with COVID-19 infection. Rev Assoc Med Bras (1992). 2020;66Suppl 2(Suppl 2):86-90. Published 2020 Sep 21. doi:10.1590/1806-9282.66.S2.86
22. 23. Liu N, Zhang T, Ma L, et al. The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. Blood Rev. 2020;(xxxx):100785. doi:10.1016/j.blre.2020.100785
23. 24. Latz CA, DeCarlo C, Boitano L, et al. Blood type and outcomes in patients with COVID-19. Ann Hematol. 2020;99(9):2113-2118. doi:10.1007/s00277-020-04169-1
24. 25. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585
25. 26. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7
26. 27. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy [published correction appears in JAMA. 2020 Apr 28;323(16):1619]. JAMA. 2020;323(18):1775-1776. doi:10.1001/jama.2020.4683
27. 28. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95. doi:10.1016/j.ijid.2020.03.017
28. 29. Espinosa OA, Zanetti ADS, Antunes EF, Longhi FG, Matos TA, Battaglini PF. Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis. Rev Inst Med Trop Sao Paulo. 2020;62:e43. Published 2020 Jun 22. doi:10.1590/S1678-9946202062043
29. 30. Lahner E, Dilaghi E, Prestigiacomo C, et al. Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy. Int J Environ Res Public Health. 2020;17(12):4417. Published 2020 Jun 19. doi:10.3390/ijerph17124417
30. 31. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020;75:107-108. doi:10.1016/j.ejim.2020.03.014